Merging and purchase (M&A) task in the pharmaceutical agreement production market decreased in 2023 contrasted to 2021-22. High rising cost of living and rates of interest together with an unsure service atmosphere disincentivized financial investment. In spite of less bargains, the emphasis moved in the direction of scaling procedures instead of getting specialist abilities, according to GlobalData, the information and analytics business.
发布者：Manufacturing Logistics IT Magazine，转转请注明出处：https://robotalks.cn/pharma-cmo-ma-activity-shifts-focus-to-scaling-in-2023-reveals-globaldata/
